LONDON – Realm Therapeutics plc has sold U.S. and U.K. specialist health care funds on its transformation from disinfection services company to immunotherapy specialist, raising £19.3 million (US$26 million) in a placing to advance its hypochlorous acid product through phase IIb in atopic dermatitis and allergic conjunctivitis.